LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Nektar Therapeutics

Затворен

0.66 -1.49

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.65

Максимум

0.68

Ключови измерители

By Trading Economics

Приходи

-58M

-51M

Продажби

-19M

10M

EPS

-0.24

Марж на печалбата

-486.444

Служители

61

EBITDA

-58M

-41M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+661.19% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

15M

148M

Предишно отваряне

2.15

Предишно затваряне

0.66

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Nektar Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.06.2025 г., 14:31 ч. UTC

Печалби

New York State Retirement Fund Posts 5.84% Annual Investment Return

6.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.06.2025 г., 20:33 ч. UTC

Печалби

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 19:36 ч. UTC

Пазарно говорене

Oil Futures Post Solid Weekly Gains -- Market Talk

6.06.2025 г., 19:28 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6.06.2025 г., 18:46 ч. UTC

Пазарно говорене

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6.06.2025 г., 18:02 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Continues to Decline -- Market Talk

6.06.2025 г., 16:35 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 16:34 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 16:21 ч. UTC

Пазарно говорене

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

6.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.06.2025 г., 16:07 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

6.06.2025 г., 16:07 ч. UTC

Пазарно говорене

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6.06.2025 г., 15:53 ч. UTC

Пазарно говорене

Mexican Inflation Seen Rising in May -- Market Talk

6.06.2025 г., 15:36 ч. UTC

Пазарно говорене

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6.06.2025 г., 15:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.06.2025 г., 15:33 ч. UTC

Пазарно говорене

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6.06.2025 г., 15:16 ч. UTC

Пазарно говорене

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6.06.2025 г., 15:05 ч. UTC

Пазарно говорене

Silver at its Highest In Nearly 15 Years -- Market Talk

6.06.2025 г., 14:35 ч. UTC

Пазарно говорене

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6.06.2025 г., 14:15 ч. UTC

Пазарно говорене

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6.06.2025 г., 14:12 ч. UTC

Печалби

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6.06.2025 г., 14:09 ч. UTC

Печалби

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Nektar Therapeutics Прогноза

Ценова цел

By TipRanks

661.19% нагоре

12-месечна прогноза

Среден 5.1 USD  661.19%

Висок 7 USD

Нисък 2 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Nektar Therapeutics през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

5

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

0.5949 / 0.7406Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.